Pluri and ZEO ScientifiX Team Up to Expand U.S. Regenerative Medicine Manufacturing and Commercialization

Key Points

• Pluri and ZEO ScientifiX announced a definitive agreement to expand their U.S. manufacturing and commercialization platform for regenerative medicine, aesthetics, wellness, and longevity.
• The agreement provides for exclusive U.S. rights to Pluri’s Cellav aesthetic product line, including future offerings, for introduction through ZEO’s commercial platform.
• Pluri would hold 50% of ZEO’s issued and outstanding common stock immediately following closing, which is expected in the fourth quarter of 2026 and remains subject to conditions.

Pluri, a biotechnology company developing cell-based products for health and longevity, and ZEO ScientifiX, a U.S. biopharmaceutical company integrating regenerative biologics research, development, manufacturing, and commercial operations, announced an agreement to expand their U.S. manufacturing and commercialization platform serving the regenerative medicine, aesthetics, wellness, and longevity markets.

ZEO brings an established U.S. biologics business with scientific and manufacturing capabilities, an existing biologics portfolio, a physician network, sales and marketing resources, and educational programming.

Pluri contributes more than two decades of experience in cell-based research, product development, clinical trials, process scale-up, quality systems, and manufacturing. Its proprietary three-dimensional cell-expansion technology and intellectual property support the development and manufacture of cell-based products and the regenerative aesthetics portfolio of its subsidiary, Cellav Health and Aesthetics Ltd.

The companies intend to combine these capabilities to broaden product offerings, expand commercial reach, and advance selected regenerative-development programs, subject to applicable regulatory requirements.

Regenerative aesthetics

The agreement provides for exclusive U.S. rights to Pluri’s Cellav aesthetic product line, including future offerings. Cellav, Pluri’s wholly owned aesthetics subsidiary, develops cell-derived ingredients and aesthetic products that the companies intend to introduce through ZEO’s commercial platform.

Product development

Pluri’s clinical-development experience includes multinational Phase III trials in muscle recovery following hip-fracture surgery and critical limb ischemia. It also has an intellectual property portfolio of more than 200 patents. The companies aim to combine Pluri’s development experience and accumulated scientific and clinical data with ZEO’s research, manufacturing, and commercial capabilities to develop and bring therapeutic products to market.

Yaky Yanay, president and chief executive officer of Pluri, said: “For Pluri, this creates an important opportunity to connect more than two decades of cell technology, clinical development, and advanced manufacturing expertise with an existing route to market.”

Transaction terms

Under the agreement, Pluri will grant ZEO defined rights to its manufacturing technology and related know-how associated with its regenerative medicine assets, while retaining ownership of the underlying technology and intellectual property. In consideration, ZEO will initially issue Pluri shares representing 50% of its issued and outstanding common stock immediately following closing. The agreement also provides for warrants, corporate governance and protective rights, as well as customary representations and warranties, covenants, and indemnifications.

Following closing, ZEO’s financial results are expected to be consolidated into Pluri’s financial statements, subject to applicable accounting requirements.

Closing is expected in the fourth quarter of 2026, subject to conditions including negotiation of ancillary agreements, certain approvals, delivery of valuations, and other customary closing conditions. The transaction is not subject to stockholder approval by either Pluri or ZEO.

Want to keep up on regenerative medicine? Get the weekly newsletter here.